lutetium has been researched along with Injuries, Radiation in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernhardt, P; Chouin, N; Cicone, F; Cremonesi, M; Eberlein, U; Gabina, PM; Gear, J; Gnesin, S; Konijnenberg, M; Sjögreen Gleisner, K; Stokke, C; Verburg, FA | 1 |
| Gans, R; Lam, M; Stam, A; van Kalmthout, L | 1 |
| Bluemel, C; Buck, AK; Eberlein, U; Lassmann, M; Nowak, C; Scherthan, H; Werner, RA | 1 |
| Bergsma, H; de Herder, WW; Franssen, GJ; Kam, BL; Konijnenberg, MW; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; van Eijck, CH | 1 |
| Ahmadzadehfar, H; Bode, A; Claesener, M; Eppard, E; Heinzel, A; Rahbar, K; Schmidt, M; Yordanova, A | 1 |
| Kesavan, M; Turner, JH | 1 |
| Ahmadzadehfar, H; Bartenstein, P; Baum, RP; Bögemann, M; Brenner, W; Drzezga, A; Essler, M; Eveslage, M; Fendler, WP; Haberkorn, U; Heinzel, A; Heuschkel, M; Kratochwil, C; Krause, BJ; Kulkarni, HR; Luster, M; Lützen, U; Marx, M; Meyer, PT; Mottaghy, FM; Pfestroff, A; Prasad, V; Rahbar, K; Ruf, J; Schäfers, M; Schmidt, M | 1 |
| Forrer, F; Giovacchini, G; Müller-Brand, J; Nicolas, G | 1 |
| Campana, B; Forrer, F; Lohri, A; Maecke, H; Mueller-Brand, J; Oechslin-Oberholzer, C | 1 |
| Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Milowski, MI; Nanus, DM; Vallabhajosula, S | 1 |
2 review(s) available for lutetium and Injuries, Radiation
| Article | Year |
|---|---|
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Temozolomide | 2016 |
Targeted radiotherapy with radiolabeled somatostatin analogs.
Topics: Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Radiation Injuries; Radioisotopes; Radionuclide Imaging; Radiotherapy; Somatostatin; Yttrium Radioisotopes | 2011 |
2 trial(s) available for lutetium and Injuries, Radiation
| Article | Year |
|---|---|
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Organometallic Compounds; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Rituximab; Treatment Outcome | 2012 |
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Body Burden; Bone Marrow; Bone Marrow Diseases; Dose-Response Relationship, Radiation; Humans; Lutetium; Male; Maximum Tolerated Dose; Middle Aged; Organ Specificity; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Yttrium Radioisotopes | 2005 |
6 other study(ies) available for lutetium and Injuries, Radiation
| Article | Year |
|---|---|
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.
Topics: Humans; Ligands; Lutetium; Male; Prostate-Specific Antigen; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin | 2022 |
Visual deficit possibly caused by lutetium-177 PSMA treatment.
Topics: Bone Neoplasms; Diagnosis, Differential; Humans; Lutetium; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Vision Disorders | 2018 |
DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy.
Topics: Aged; DNA Breaks, Double-Stranded; Dose-Response Relationship, Radiation; Female; Humans; Lutetium; Lymphocytes; Male; Middle Aged; Radiation Injuries; Radioisotopes; Radiotherapy Dosage; Receptors, Peptide; Time Factors | 2015 |
Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Topics: Aged; Bone Marrow; Female; Humans; Iodine; Lutetium; Male; Middle Aged; Netherlands; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Prognosis; Prospective Studies; Radiation Injuries; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptors, Peptide; Risk Factors; Treatment Outcome | 2016 |
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Dipeptides; Dose-Response Relationship, Drug; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2016 |
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Causality; Comorbidity; Dipeptides; Germany; Hematologic Diseases; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Prevalence; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Treatment Outcome | 2017 |